Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 13/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26382111 | 1.00 | AHCY (1.00) | AHCYADORA2AADORA3 | |
| Hydrochloric Acid SCHEMBL1935723 | 0.99 | AHCY (0.97) | AHCYADORA2AADORA3 | |
| SCHEMBL26382007 | 0.86 | AHCY (0.76) | AHCYADORA3 | |
| SCHEMBL26382114 | 0.85 | AHCY (0.74) | AHCYADORA2AADORA3 | |
| SCHEMBL12280183 | 0.83 | AHCY (0.80) | AHCYADORA2AADORA3 | |
| Neoplanocin A SCHEMBL12157269 | 0.82 | AHCY (1.00) | AHCYADORA2AADORA3 | |
| Neoplanocin A SCHEMBL10576831 | 0.82 | AHCY (1.00) | AHCYADORA2AADORA3 | |
| Neoplanocin A SCHEMBL863873 | 0.82 | AHCY (1.00) | AHCYADORA2AADORA3 | |
| Neoplanocin A SCHEMBL17117192 | 0.82 | AHCY (1.00) | AHCYADORA2AADORA3 | |
| SCHEMBL864418 | 0.82 | AHCY (0.81) | AHCY |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237606-A1 | 3-Deazaneplanocin Derivatives | AGENCY OF SCIENCE, TECHNOLOGY AND RESEARCH | 2011-09-29 | — | — | US | disclosed |
| US-20110237606-A1 | 3-Deazaneplanocin Derivatives | AGENCY OF SCIENCE, TECHNOLOGY AND RESEARCH | 2011-09-29 | — | — | US | disclosed |
| WO-2010036213-A1 | 3-DEAZANEPLANOCIN DERIVATIVES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237606-A1 | 3-Deazaneplanocin Derivatives | EZH2, SUZ12, DAZAP1 | AHCY 4001/4885ADORA2A 4784/4885ADORA3 4816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.